Socioeconomic disparities causing delays in pancreatic cancer germline genetic testing.

Authors

null

Xianghui Zou

Department of Internal Medicine, North Shore University Hospital & Long Island Jewish Medical Center, New Hyde Park, NY;

Xianghui Zou , Daniel King , Baho Sidiqi , Sunita Patruni , Christopher Hollweg , Noah D. Kauff

Organizations

Department of Internal Medicine, North Shore University Hospital & Long Island Jewish Medical Center, New Hyde Park, NY; , Northwell Health Cancer Institute and Feinstein Institute of Research, Lake Success, NY; , Division of Radiation Medicine, Northwell Health Cancer Institute, New Hyde Park, NY; , Division of Medical Oncology/Hematology, North Shore University Hospital & Long Island Jewish Medical Center, New Hyde Park, NY; , Division of Clinical Informatics, Northwell Health, New York, NY; , Division of Cancer Genetics, Northwell Health, New York, NY;

Research Funding

No funding received
None.

Background: Germline genetic testing is recommended for patients with pancreatic ductal adenocarcinoma (PDAC) and pre-diagnostic testing is offered to patients with a significant family history. However, only 36% of patients in our institution obtained genetic testing. We identified associations between patient social profiles (income, race, ethnicity, social work needs) and delays in obtaining germline genetic testing from New York’s largest healthcare system. Methods: Patients with PDAC were identified using billing records across our institution with an IRB-approved protocol. Median income was extrapolated using patient zip code. Date of diagnosis (DOD) was recorded as the date of biopsy or, if no biopsy was performed, the date of earliest lesion found on CT scan. Delays of testing was calculated as the difference between DOD and the date of germline sample collection. Results: Between Mar 2016 and Feb 2022, 305 patients with PDAC were identified, with 103 (36.3%) having reports found (F), and 202 (63.7%) not having reports found (NF). Availability of germline testing did not vary by median income (F: $95954, NF: $94368, t=0.414, p=0.68). There was no significant difference in the geographic distribution either (gender p=0.92, race p=0.92, ethnicity p=0.16). Pearson analysis between income (x) and delays of testing (y) showed a negative correlation (y=-0.0028x+316, r2=0.058, p=0.014). African American and Hispanic patients, grouped for this analysis as underserved (U), had a significant delay in obtaining germline genetic testing compared to the remainder of patients (not underserved, NU) (U: 92d, NU: 21d, u=305.5, p=0.0016). In addition, African American (AA) patients had a significant delay of testing compared to White (W) patients (AA: 92d, W: 13d, u=161.5, p=0.0002). Furthermore, all 11 patients (1 Asian, 10 White) who obtained pre-diagnostic testing were NU patients (χ2=5.005, p=0.025). Upon further analysis, patients who have social work (SW) needs have a significant delay in testing compared to patients without SW needs (SW: 109d, no SW: 23d, u=263, p=0.025). Of the 12 patients who have SW needs, the primary needs were home care, transportation, or financial assistance. In addition, there was a trend toward difference between English (E) and non-English (NE) speaking patients when comparing their delays in testing (E=26.5, NE=108.5, u=257, p=0.12). Conclusions: Analysis of germline and clinical data from our 305-patient cohort identified a striking and concerning negative correlation between patient income and delays in germline testing. In addition, underserved patients had significant delays in germline testing and did not obtain any pre-diagnostic testing. Furthermore, social needs and primary language may be barriers for germline testing. Interprofessional collaborations may be required to prompt germline testing at our institution or nationwide.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Cancer Disparities

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 665)

DOI

10.1200/JCO.2023.41.4_suppl.665

Abstract #

665

Poster Bd #

H9

Abstract Disclosures

Similar Abstracts

First Author: Xianghui Zou

First Author: Xianghui Zou

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Assessing disparities in pancreatic cancer outcomes in African Americans.

First Author: Shiva Shrotriya

Abstract

2023 ASCO Annual Meeting

Evaluating disparities in pancreatic cancer outcomes in African Americans.

First Author: Shiva Shrotriya